JPH0772128B2 - 製薬組成物及びその製法 - Google Patents
製薬組成物及びその製法Info
- Publication number
- JPH0772128B2 JPH0772128B2 JP60110061A JP11006185A JPH0772128B2 JP H0772128 B2 JPH0772128 B2 JP H0772128B2 JP 60110061 A JP60110061 A JP 60110061A JP 11006185 A JP11006185 A JP 11006185A JP H0772128 B2 JPH0772128 B2 JP H0772128B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- silica
- liquid
- silicate
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 65
- 239000007788 liquid Substances 0.000 claims description 33
- 239000000377 silicon dioxide Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 26
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000002745 absorbent Effects 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- -1 antibacterial drug Substances 0.000 claims description 2
- 229940124350 antibacterial drug Drugs 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940127088 antihypertensive drug Drugs 0.000 claims description 2
- 239000003699 antiulcer agent Substances 0.000 claims description 2
- 230000003177 cardiotonic effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000003204 tranquilizing agent Substances 0.000 claims description 2
- 230000002936 tranquilizing effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000000378 calcium silicate Substances 0.000 claims 1
- 229910052918 calcium silicate Inorganic materials 0.000 claims 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 1
- 229940125725 tranquilizer Drugs 0.000 claims 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 5
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 5
- 239000007963 capsule composition Substances 0.000 description 5
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 5
- 229960005156 digoxin Drugs 0.000 description 5
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 150000004760 silicates Chemical class 0.000 description 5
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960004423 ketazolam Drugs 0.000 description 3
- PWAJCNITSBZRBL-UHFFFAOYSA-N ketazolam Chemical compound O1C(C)=CC(=O)N2CC(=O)N(C)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1 PWAJCNITSBZRBL-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000014483 powder concentrate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UKGACSZPWMARJQ-UHFFFAOYSA-N 2,3-diacetyloxypropyl acetate;propan-2-yl tetradecanoate Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O.CCCCCCCCCCCCCC(=O)OC(C)C UKGACSZPWMARJQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005949 Malathion Substances 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960000453 malathion Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848413191A GB8413191D0 (en) | 1984-05-23 | 1984-05-23 | Pharmaceutical composition |
| GB8413191 | 1984-05-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60258113A JPS60258113A (ja) | 1985-12-20 |
| JPH0772128B2 true JPH0772128B2 (ja) | 1995-08-02 |
Family
ID=10561403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60110061A Expired - Lifetime JPH0772128B2 (ja) | 1984-05-23 | 1985-05-22 | 製薬組成物及びその製法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US4719228A (instruction) |
| EP (1) | EP0163178B1 (instruction) |
| JP (1) | JPH0772128B2 (instruction) |
| CA (1) | CA1255222A (instruction) |
| DE (1) | DE3580304D1 (instruction) |
| ES (1) | ES8800039A1 (instruction) |
| GB (1) | GB8413191D0 (instruction) |
| GR (1) | GR851254B (instruction) |
| IE (1) | IE57732B1 (instruction) |
| MX (1) | MX163564B (instruction) |
| NZ (1) | NZ212148A (instruction) |
| ZA (1) | ZA853823B (instruction) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5248700A (en) * | 1982-05-14 | 1993-09-28 | Akzo Nv | Active agent containing solid structures for prolonged release of active agents |
| JPS6245537A (ja) * | 1985-08-23 | 1987-02-27 | Sumitomo Electric Ind Ltd | 医用樹脂組成物及びその製造方法 |
| JPH0621072B2 (ja) * | 1986-11-12 | 1994-03-23 | 呉羽化学工業株式会社 | エストラジオ−ル誘導体よりなる免疫調節剤 |
| US4837255A (en) * | 1987-03-10 | 1989-06-06 | Ciba-Geigy Corporation | Palatable hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin |
| US4898736A (en) * | 1988-03-09 | 1990-02-06 | Merck & Co., Inc. | Method for tablet preparation |
| IE60458B1 (en) * | 1989-10-26 | 1994-07-13 | Elan Corp Plc | Enhanced bioavailability adsorbates |
| US5030446A (en) * | 1990-01-24 | 1991-07-09 | Revlon, Inc. | Oil- and talc-free cosmetic powder composition |
| DK0448091T3 (da) * | 1990-03-23 | 1999-05-03 | Yoshitomi Pharmaceutical | Farmaceutisk præparat indeholdende et i ringe grad vandopløseligt medikament |
| DE69209942T2 (de) * | 1991-09-05 | 1996-09-05 | Tsumura & Co | Verfahren zum Herstellen Hartgelatinekapseln, die chinesische Kräuterextrakte enthalten |
| US5622980A (en) * | 1993-08-17 | 1997-04-22 | Applied Analytical Industries, Inc. | Oral compositions of H2-antagonists |
| DE19506141A1 (de) | 1995-02-22 | 1996-08-29 | Hoechst Ag | Verwendung von Aerogelen in der Pharmazie, in der Kosmetik und im Pflanzenschutz |
| US5766668A (en) * | 1995-03-27 | 1998-06-16 | Chinook Group, Inc. | Method for synthesizing chloride based feed precursor and product resulting therefrom |
| SE9704400D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | Porous inorganic particles as carriers for drug substances |
| DE19825687A1 (de) * | 1998-06-09 | 1999-12-16 | Degussa | Wirkstoffkonzentrat |
| US6303167B1 (en) * | 1998-11-09 | 2001-10-16 | Archer-Daniels-Midland Company | Method of producing vitamin powders |
| ATE306250T1 (de) * | 1998-12-23 | 2005-10-15 | Alza Corp | Dosierungsformen, die poröse partikel enthalten |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| EP1469832B2 (en) * | 2002-02-01 | 2016-10-26 | Bend Research, Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
| EP1358805A1 (en) * | 2002-04-30 | 2003-11-05 | Aventis Animal Nutrition S.A. | Animal feed supplement |
| US20060115524A1 (en) * | 2003-02-19 | 2006-06-01 | H. Lundbeck A/S | Method for preparation of an agglomerate using melt agglomeration |
| CA2516096A1 (en) * | 2003-02-19 | 2004-09-02 | Lifecycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
| BRPI0413277A (pt) * | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas |
| US7658944B2 (en) * | 2003-10-10 | 2010-02-09 | Lifecycle Pharma A/S | Solid dosage form comprising a fibrate |
| US9173847B2 (en) * | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
| EP1680086A2 (en) * | 2003-10-10 | 2006-07-19 | LifeCycle Pharma A/S | A solid dosage form comprising a fibrate and a statin |
| US20050096390A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and pravastatin |
| AR046901A1 (es) * | 2003-12-17 | 2005-12-28 | Schering Corp | Composiciones farmaceuticas |
| EP2353590A1 (en) * | 2005-02-15 | 2011-08-10 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
| EP3689353A1 (en) | 2007-02-23 | 2020-08-05 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| PL2296633T3 (pl) | 2008-05-02 | 2016-03-31 | Gilead Sciences Inc | Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego |
| US8535392B2 (en) * | 2008-11-25 | 2013-09-17 | Milliken & Company | Solid polymeric colorant compositions |
| WO2019145557A1 (en) * | 2018-01-29 | 2019-08-01 | Specialites Pet Food | Litter for promoting pet's in-litter elimination |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2879161A (en) * | 1956-05-14 | 1959-03-24 | American Cyanamid Co | Stable dry powder compositions containing choline chloride and methods of preparing same |
| US3085942A (en) * | 1960-12-28 | 1963-04-16 | Hoffmann La Roche | Antitussive compositions and preparation |
| SE421042B (sv) * | 1976-06-29 | 1981-11-23 | Kockums Chem | Sett att minska den for en viss biologisk effekt erforderliga mengden biologiskt aktiv substans |
| DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
| DE3274350D1 (en) * | 1981-09-25 | 1987-01-08 | Beecham Group Plc | Pharmaceutically active benzopyran compounds |
| US4581232A (en) * | 1983-07-20 | 1986-04-08 | Warner-Lambert Company | Magnesium trisilicate suitable for preparation of medicament adsorbates |
| DE3409063A1 (de) * | 1984-03-13 | 1985-09-19 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von fliessfaehigen cholinchlorid-kieselsaeure-pulvern |
-
1984
- 1984-05-23 GB GB848413191A patent/GB8413191D0/en active Pending
-
1985
- 1985-05-10 EP EP85105731A patent/EP0163178B1/en not_active Expired - Lifetime
- 1985-05-10 DE DE8585105731T patent/DE3580304D1/de not_active Revoked
- 1985-05-17 MX MX8235A patent/MX163564B/es unknown
- 1985-05-21 GR GR851254A patent/GR851254B/el unknown
- 1985-05-21 IE IE1262/85A patent/IE57732B1/en not_active IP Right Cessation
- 1985-05-21 US US06/736,337 patent/US4719228A/en not_active Expired - Lifetime
- 1985-05-21 NZ NZ212148A patent/NZ212148A/xx unknown
- 1985-05-21 ZA ZA853823A patent/ZA853823B/xx unknown
- 1985-05-21 CA CA000481950A patent/CA1255222A/en not_active Expired
- 1985-05-22 ES ES543401A patent/ES8800039A1/es not_active Expired
- 1985-05-22 JP JP60110061A patent/JPH0772128B2/ja not_active Expired - Lifetime
-
1987
- 1987-10-26 US US07/115,589 patent/US4859709A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA1255222A (en) | 1989-06-06 |
| US4859709A (en) | 1989-08-22 |
| GR851254B (instruction) | 1985-11-25 |
| JPS60258113A (ja) | 1985-12-20 |
| MX163564B (es) | 1992-06-01 |
| NZ212148A (en) | 1989-01-06 |
| IE851262L (en) | 1985-11-23 |
| AU4280085A (en) | 1985-11-28 |
| ES543401A0 (es) | 1987-11-01 |
| DE3580304D1 (de) | 1990-12-06 |
| ZA853823B (en) | 1986-04-30 |
| AU589561B2 (en) | 1989-10-19 |
| US4719228A (en) | 1988-01-12 |
| EP0163178A3 (en) | 1987-01-14 |
| EP0163178A2 (en) | 1985-12-04 |
| EP0163178B1 (en) | 1990-10-31 |
| GB8413191D0 (en) | 1984-06-27 |
| IE57732B1 (en) | 1993-03-24 |
| ES8800039A1 (es) | 1987-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0772128B2 (ja) | 製薬組成物及びその製法 | |
| ES2718273T5 (en) | Tablet formulation of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis | |
| US5800834A (en) | Liquisolid systems and methods of preparing same | |
| SE508343C2 (sv) | Läkemedelsadsorbat | |
| KR20110016921A (ko) | 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 용량형을 제조하는 방법 | |
| WO1995009626A1 (en) | Mycophenolate mofetil high dose oral suspensions | |
| JPS62501908A (ja) | 薬理的組成物及びそれを含有する薬理的製剤 | |
| US5028432A (en) | Pharmaceutical capsules containing panetidine | |
| AU752044B2 (en) | Porous hydroxyapatite particles as carriers for drug substances | |
| CN112353845B (zh) | 含中药挥发油的热熔挤出组合物及其制备方法和药物制剂 | |
| JPS6230965B2 (instruction) | ||
| EP1929997A1 (en) | Oxcarbazepine formulations | |
| JP2002501015A (ja) | リーシュマニア症の治療における経口投与のためのミルテフォシンを含有する固形医薬品 | |
| JPH0142923B2 (instruction) | ||
| JPS62142118A (ja) | 経口にんにく製剤およびその製造法 | |
| KR20030024833A (ko) | 시탈로프람을 함유하는 약학 조성물 | |
| JP2626975B2 (ja) | 低融点油性物質含有錠剤 | |
| EP0326103B1 (en) | Pharmaceutical composition for 4-aroylimidazol-2-ones | |
| JPS6351122B2 (instruction) | ||
| RU2302233C2 (ru) | Масляные тиксотропные композиции | |
| JPS59101420A (ja) | インドメタシンを含有する直腸用調製物 | |
| JP2002037727A (ja) | 脂溶性薬物を配合した速崩性固形製剤及びその製造方法 | |
| JPS63115815A (ja) | 肝疾患治療薬組成物 | |
| JP2002226363A (ja) | 難溶性薬物を含有する複合粒固形製剤 | |
| CA1068608A (en) | Pharmaceutical composition containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |